Abstract Long-acting cabotegravir/rilpivirine (LA-CAB/RPV) is the first and only complete injectable HIV regimen, approved in the United States (U.S.) in 2021 for individuals who are virologically suppressed. While clinical trials have demonstrated efficacy, real-world implementation remains underexplored. We conducted a cross-sectional survey of members and credentialed clinicians who are front line HIV providers of the American Academy of HIV Medicine between July and August 2024. Overall, LA-CAB/RPV has been widely adopted in U.S. HIV care, but structural, financial, and clinical barriers persist. Standardized guidance is needed to expand data in youth, persons with obesity, and other special populations. Strategies to address healthcare infrastructure barriers are essential to optimize uptake and equitable access.
Short et al. (2026) studied this question.